疫苗前沿 | 有望半年一针控制高血压！创新RNAi疗法启动2期临床试验

 

参考资料:

[1] Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension. Retrieved November 8, 2021, from https://www.businesswire.com/news/home/20211108005384/en

[2] Safety, Pharmacodynamics, and Blood Pressure Effects of ALN-AGT, an RNA Interference Therapeutic Targeting Angiotensinogen, in a Randomized Single Ascending Dose Study of Hypertensive Adults. Retrieved April 11, 2021, from https://www.alnylam.com/wp-content/uploads/2021/04/Safety-Pharmacodynamics-and-Blood-Pressure-Effects-of-ALN-AGT-an-RNA-Interference-Therapeutic-Targeting-Angiotensinogen-in-a-Randomized-Single-Ascending-Dose-Study-of-Hypertensive-Adults.pdf

来源：药明康德

打赏